Outcome Capital, a highly specialized life science and healthcare investment banking group, today announced the formal launch of an Advisory Services Practice in response to demand from client companies and their Boards for earlier access to Outcome’s broad scientific, clinical, financial and strategy capabilities. The firm’s advisory services will include bespoke tax and accounting solutions provided by Michaele Esdale, PhD, CPA, who joined the firm earlier this year.
“We are excited to offer our Advisory Practice as a complement to our investment banking services, and Michaele’s deep accounting background deepens the breadth of our services to enable full-scope analysis. Her additional services will provide our clients with end-to-end, strategy creation to financial service offerings that clients will benefit from significantly,”
- Arnold Freedman
To meet Outcome’s deep commitment to the life science sector, the firm has already assisted numerous innovative companies, family offices and venture firms seeking “pre-transaction” guidance and support in anticipation of future exit events and capital requirements. The company will now formally offer life science and healthcare management, Boards and investors with access to the firm’s strategic and financial expertise through the new Advisory Services Practice. Services provided will include proprietary data and analytics platforms, modeling and valuation frameworks, portfolio management expertise, financial statement analysis, earnings optimization, exit planning and scenario analysis, along with a myriad of corporate development services.
In addition to Dr. Esdale, these services will be provided by Outcome’s legacy strategy and finance groups, led by Co-Founders and Managing Directors Oded Ben-Joseph, PhD, MBA and Arnold Freedman, along with senior management: Ellen Baron, PhD; Paul Mieyal, PhD, CFA; Karl Hess; Craig Steger; Michael Casasanta, PhD; Thomas Busby and Nicholas Frame, PhD.
Dr. Ben-Joseph commented, Technologies can all too easily drift from what the market is truly seeking, and a strong corporate development function reduces extraneous costs and increases the likelihood of transacting. Curiously, however, one of the last positions filled for many life science companies is related to corporate development, which is an instrumental role in our industry. Since Outcome’s inception, we have found management teams at a disadvantage when initiating transaction work too late and we often represent clients who have conveyed their regret in not engaging sooner after seeing the benefits we can offer. Therefore, although our team has already been undertaking this strategic work routinely, we are looking forward to formally offering services to address these corporate development needs.
Dr. Esdale is a CPA with over twenty years of experience spanning accounting and taxation in a variety of senior public and private roles. Prior to Outcome Capital, Dr. Esdale spent nearly two decades in academia, authoring over 30 publications in both academic and professional journals. Concurrent to her time in academia, Dr. Esdale was a national tax instructor for PwC and KPMG, where she taught a wide variety of topics including mergers and acquisitions, corporate tax and the ins and outs of net operating losses. Dr. Esdale’s operational expertise includes CFO and COO positions for a technology company that provided clinical trial data-sharing software to multinational pharmaceutical companies. She is a 2019 Boston Business Journal 40 Under 40 Honoree.
Dr. Esdale commented, I am looking forward to the opportunity to assist growth-stage companies with business optimization strategies. The financial advisory services we provide assist in maximizing current profitability and instituting best practices, while also serving to implement necessary infrastructure for future growth and exit strategies.
About Outcome Capital
Outcome Capital is a highly specialized life science and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success.
The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, our team is driven to propel innovation from bench to bedside.